SMTI Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2016βFY2025
Sanara MedTech Inc. had $103M of revenue in fiscal 2025, up 19.0% on the year before. Over five years, revenue changed +45.9% a year on average.
Last close Β· Oct 23, 2026
$32.80
0.2%Hi! I read Sanara MedTech Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+19.0%
Yes. Sales grew 19.0% last year.
Does it make a profit?
β36.4%
No. It lost money last year.
Does profit turn into cash?
2.1%
Partly. 2.1% of sales ends up as free cash.
Is debt under control?
2.6x
Keep an eye on it. Repaying its debt would take 2.6 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Sanara MedTech Inc. had $103M of revenue in fiscal 2025, up 19.0% on the year before. Over five years, revenue changed +45.9% a year on average. Its operating margin was 7.1%, up 5.6Β pts: of every 100 in sales, about 7 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Sanara MedTech Inc. lost $37.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $2.2M in fiscal 2025, 2.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Sanara MedTech Inc. owes $29.4M more than it holds in cash, about 2.6 years of operating profit.
Cash, debt and the ratios that show how comfortably Sanara MedTech Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $18.7M | $9.0M | $5.1M | $15.9M | $16.6M |
| Debt incl. finance leases | β | β | $9.7M | $30.7M | $46.0M |
| Net debt / EBITDA | β | β | β | 2.4x | 2.6x |
| Debt / equity | β | β | 0.2x | 0.8x | 7.7x |
| Interest coverage | β10,537.4x | β44.0x | β8.9x | 0.4x | 1.1x |
| Current ratio | 4.1x | 1.6x | 1.4x | 2.2x | 1.8x |
| Quick ratio | 3.7x | 1.3x | 1.0x | 2.0x | 1.6x |
| Total assets | $36.4M | $61.0M | $73.9M | $88.1M | $72.9M |
| Total liabilities | $6.2M | $19.3M | $29.3M | $49.2M | $67.0M |
| Shareholders' equity | $30.6M | $41.8M | $44.8M | $39.4M | $5.9M |
| Net debt (β = net cash) | β | β | $4.5M | $14.8M | $29.4M |
KIRA Β· Its return on capital was 16.3%: every 100 invested in the business earned about 16 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Sanara MedTech Inc. passes 4 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 5 / 8 | 4 / 8 | 2 / 8 | 4 / 8 | 3 / 8 | 4 / 8 | 4 / 9 | 4 / 9 |
| Accruals ratio | β38.0% | 21.5% | β44.7% | β10.1% | β3.9% | β13.4% | β4.9% | β1.6% | β11.9% | β55.1% |
| Altman Z'' | β70.06 | β68.70 | 1.02 | 2.65 | β3.53 | 5.78 | 0.49 | 0.45 | 0.88 | β1.26 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.5M | $6.3M | $5.8M | $11.8M | $15.6M | $24.1M | $45.8M | $65.0M | $86.7M | $103M |
| Gross profit | $4.6M | $5.5M | $5.3M | $10.6M | $14.0M | $21.8M | $39.5M | $57.1M | $78.5M | $95.6M |
| Research and development | β | β | β | β | $0.0M | $0.6M | $3.4M | $4.1M | $2.8M | $5.1M |
| Operating income | β$0.3M | $0.1M | β$0.5M | β$2.7M | β$5.0M | β$7.4M | β$12.5M | β$4.2M | $1.3M | $7.3M |
| Interest expense | $0.2M | $0.1M | $0.1M | $0.1M | $0.0M | $0.0M | $0.3M | $0.5M | $3.1M | $6.8M |
| Pretax income | β | β | β | β | β | β$8.0M | β$13.9M | β$4.4M | β$1.9M | β$0.4M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β$5.8M | β | $0.0M | β |
| Net income | β$0.4M | $0.3M | β$0.6M | β$2.8M | β$4.4M | β$7.9M | β$7.9M | β$4.3M | β$9.7M | β$37.6M |
| Net income to common | β$0.7M | $0.2M | β$0.7M | β | β$4.4M | β$7.9M | β | β | β | β |
| Diluted EPS | β$0.01 | $0.00 | $0.00 | β$1.32 | β$0.76 | β$1.08 | β$1.00 | β$0.52 | β$1.14 | β$4.36 |
| Diluted shares | 0.11B | 0.21B | 0.22B | 0.00B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | $0.4M | β$0.1M | $0.3M | β$2.2M | β$4.0M | β$4.8M | β$5.6M | β$3.2M | β$0.0M | $6.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.2M | $0.5M | $0.2M | $0.1M | $0.3M | $0.2M | $4.6M |
| Free cash flow | $0.4M | β$0.2M | $0.3M | β$2.4M | β$4.6M | β$5.0M | β$5.7M | β$3.5M | β$0.2M | $2.2M |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M | $0.1M | $0.3M | $0.6M | $2.4M | $3.7M | $4.9M | $3.9M |
| Stock-based compensation | β | β | β | $0.0M | $1.4M | $2.7M | $2.7M | $3.4M | $4.4M | $5.2M |
| Acquisitions | β | β | β | β | β | β | β | $9.9M | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.8M | $0.5M | $0.2M | $6.6M | $0.5M | $18.7M | $9.0M | $5.1M | $15.9M | $16.6M |
| Total debt | β | β | β | $0.0M | β | β | β | $9.7M | $30.7M | $46.0M |
| Current assets | $2.0M | $2.0M | $1.7M | $8.9M | $4.5M | $24.6M | $20.6M | $19.0M | $33.3M | $33.5M |
| Current liabilities | $1.4M | $2.1M | $1.1M | $2.6M | $3.5M | $6.0M | $12.8M | $13.8M | $15.3M | $18.6M |
| Inventory | $0.3M | $0.7M | $0.5M | $0.7M | $1.1M | $2.0M | $3.5M | $4.7M | $2.8M | $3.9M |
| Property and equipment, net | $0.0M | $0.1M | $0.0M | $0.2M | $0.7M | $1.6M | $1.4M | $1.3M | $0.4M | $0.5M |
| Goodwill | β | β | β | β | β | β | $3.6M | $3.6M | $3.6M | $3.6M |
| Intangible assets | $0.1M | $0.1M | $0.0M | $1.5M | $3.1M | $4.7M | $31.5M | $44.9M | $23.5M | $18.6M |
| Total assets | $2.2M | $2.2M | $1.7M | $11.1M | $9.8M | $36.4M | $61.0M | $73.9M | $88.1M | $72.9M |
| Total liabilities | $2.6M | $2.1M | $1.1M | $4.7M | $4.0M | $6.2M | $19.3M | $29.3M | $49.2M | $67.0M |
| Preferred stock | $0.9M | $0.9M | $11.4M | $11.4M | $0.0M | β | β | β | β | β |
| Shareholders' equity | β$0.4M | $0.1M | $0.6M | $6.4M | $6.2M | $30.6M | $41.8M | $44.8M | $39.4M | $5.9M |
| Margins | ||||||||||
| Gross margin | 82.9% | 87.2% | 91.3% | 89.7% | 89.6% | 90.4% | 86.1% | 87.9% | 90.6% | 92.7% |
| Operating margin | β4.9% | 1.9% | β8.6% | β23.3% | β32.3% | β30.6% | β27.3% | β6.5% | 1.5% | 7.1% |
| EBITDA margin | β3.8% | 3.2% | β7.2% | β22.3% | β30.4% | β28.1% | β22.1% | β0.8% | 7.1% | 10.9% |
| Net margin | β7.5% | 5.3% | β10.3% | β23.9% | β28.5% | β32.8% | β17.3% | β6.6% | β11.2% | β36.4% |
| FCF margin | 7.4% | β2.9% | 4.6% | β20.0% | β29.4% | β20.7% | β12.4% | β5.4% | β0.3% | 2.1% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β6.7% | 1.8% | 16.3% |
| Return on capital employed | β35.0% | 117.3% | β85.5% | β32.3% | β80.1% | β24.3% | β26.0% | β7.0% | 1.7% | 13.4% |
| Return on equity | β | β | β174.3% | β80.6% | β70.9% | β43.1% | β21.9% | β9.9% | β22.9% | β165.7% |
| Return on assets | β19.1% | 15.1% | β30.6% | β43.9% | β42.4% | β34.3% | β16.3% | β6.4% | β11.9% | β46.7% |
| Return on tangible equity | β | β | β124.7% | β57.2% | β142.7% | β30.6% | β118.2% | β | β78.4% | β |
| Growth | ||||||||||
| Revenue growth | β | 14.5% | β7.4% | 101.6% | 32.5% | 54.9% | 89.9% | 41.8% | 33.4% | 19.0% |
| Net income growth | β | β | β281.3% | β | β | β | β | β | β | β |
| FCF growth | β | β145.2% | β | β975.0% | β | β | β | β | β | β |
| Share count change | β | 92.1% | 4.1% | β99.0% | 168.9% | 28.0% | 7.7% | 4.7% | 2.5% | 1.6% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β | 2.4x | 2.6x |
| Debt / equity | β | β | β | 0.0x | β | β | β | 0.2x | 0.8x | 7.7x |
| Interest coverage | β1.6x | 0.9x | β5.8x | β25.9x | β437.8x | β10,537.4x | β44.0x | β8.9x | 0.4x | 1.1x |
| Current ratio | 1.4x | 1.0x | 1.5x | 3.4x | 1.3x | 4.1x | 1.6x | 1.4x | 2.2x | 1.8x |
| Quick ratio | 1.2x | 0.6x | 1.1x | 3.1x | 0.9x | 3.7x | 1.3x | 1.0x | 2.0x | 1.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.1% | 0.7% | 0.1% | 1.6% | 3.5% | 0.7% | 0.3% | 0.4% | 0.2% | 4.5% |
| Stock comp / revenue | β | β | β | 0.0% | 9.0% | 11.1% | 5.9% | 5.3% | 5.1% | 5.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 5.0 | 4.0 | 2.0 | 4.0 | 3.0 | 4.0 | 4.0 | 4.0 |
| Altman Z'' | β70.1 | β68.7 | 1.0 | 2.6 | β3.5 | 5.8 | 0.5 | 0.5 | 0.9 | β1.3 |
| Accruals ratio | β38.0% | 21.5% | β44.7% | β10.1% | β3.9% | β13.4% | β4.9% | β1.6% | β11.9% | β55.1% |
Source: SEC EDGAR XBRL filings (CIK 0000714256). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
